Patent of Eli-Lilly's Blockbuster Lung Cancer Drug Alimta Upheld

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.
Published Online: April 01, 2014

Eli Lilly was successful in a crucial legal battle on Monday when a U.S. District Judge in Indianapolis upheld the validity of its U.S. patent for the drugmaker' s blockbuster lung-cancer drug, Alimta.

The court said the defendants, Teva Pharmaceutical Industries Ltd, APP Pharmaceutical, now known as Fresenius Kabi USA LLC, Barr Laboratories Inc and Pliva Hrvatska D.O.O., failed to show by clear evidence that the asserted claims of the '209 Patent are invalid.

However, the decision that would preserve the $2.6 billion-a-year drug from generic competition until 2022, could change if generic drug companies appeal the ruling.

Read the complete report here: 
http://reut.rs/1s2sdUK

Source: Reuters



Feature
Recommended Articles
With a growing understanding of the risk of cardiotoxicity associated with cancer treatment, cardio-oncology has emerged as an important subspecialty, resulting in the establishment of cardio-oncology programs most often based at or in collaboration with comprehensive cancer centers.
During this one-on-one interview, a part of the Oncology Stakeholders Summit, Spring 2015 series, Michael Kolodziej, MD, discusses payer considerations regarding coverage for new cancer treatments such as immuno-oncology therapies.
Metastatic colorectal cancer patients with higher body mass index (BMI) outlived patients with the lowest BMI by an average of 2-and-a-half months, according to new data presented at the European Society for Medical Oncology 17th World Congress on Gastrointestinal Cancer 2015.
Genevieve Kumapley, PharmD, BCOP, discusses the importance of introducing palliative care to patients at the time of diagnosis and explains how a multidisciplinary team approach can affect the utilization of healthcare resources.
During this Insights interview with Genevieve Kumapley, PharmD, BCOP, on the Use of Oral Oncolytics in Palliative Care, part of the Oncology Stakeholders Summit, Spring 2015 series, Dr Kumapley discusses current guidelines for the delivery of palliative care and describes gaps in care.